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Introduction: Administration of bone marrow-derived cells produces beneficial effects in experimental
extrapulmonary acute respiratory distress syndrome (ARDS). However, there are controversies regarding the effects
of timing of cell administration and initial insult severity on inflammatory response. We evaluated the effects of
bone marrow-derived mononuclear cells (BMDMC) in two models of extrapulmonary ARDS once lung
morphofunctional changes had already been installed.
Methods: BALB/c mice received lipopolysaccharide (LPS) intraperitoneally (5 mg/kg in 0.5 ml saline) or underwent
cecal ligation and puncture (CLP). Control mice received saline intraperitoneally (0.5 ml) or underwent sham
surgery. At 24 hours, groups were further randomized to receive saline or BMDMC (2 × 106) intravenously. Lung
mechanics, histology, and humoral and cellular parameters of lung inflammation and remodeling were analyzed 1,
3 and 7 days after ARDS induction.
Results: BMDMC therapy led to improved survival in the CLP group, reduced lung elastance, alveolar collapse,
tissue and bronchoalveolar lavage fluid cellularity, collagen fiber content, and interleukin-1β and increased
chemokine (keratinocyte-derived chemokine and monocyte chemotactic protein-1) expression in lung tissue
regardless of the experimental ARDS model. Intercellular adhesion molecule-1 and vascular cell adhesion
molecule-1 expression in lung tissue increased after cell therapy depending on the insult (LPS or CLP).
Conclusions: BMDMC therapy at day 1 successfully reduced lung inflammation and remodeling, thus contributing
to improvement of lung mechanics in both extrapulmonary ARDS models. Nevertheless, the different inflammatory
responses induced by LPS and CLP resulted in distinct effects of BMDMC therapy. These data may be useful in the
clinical setting, as they suggest that the type of initial insult plays a key role in the outcome of treatment.* Correspondence: prmrocco@biof.ufrj.br
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Acute respiratory distress syndrome (ARDS) is a multifa-
ceted syndrome with a wide-ranging clinical phenotype,
making it a challenge to translate experimental results
into feasible therapies in the clinical setting [1]. Several
studies have addressed the therapeutic benefits of bone
marrow-derived cells, such as bone marrow-derived
mononuclear cells (BMDMCs) and mesenchymal stro-
mal cells, in murine models of extrapulmonary ARDS
induced by intraperitoneal administration of Escherichia
coli lipopolysaccharide (LPS) [2,3] and cecal ligation and
puncture (CLP) [4-6]. Bone marrow-derived cells have
been shown to mitigate systemic and pulmonary in-
flammation, as well as decrease lung edema and en-
hance bacterial clearance, resulting in lower mortality
[2,4-7]. Nevertheless, the potential effects of the sever-
ity of ARDS on inflammatory response and the time
course for lung damage, which may play a role in the
outcome of treatments [8], have not been addressed in
the literature. It may also be argued that these effects
are mediated by the specific characteristics of different
types of injury.
In the present study, the beneficial effects of cell ther-
apy were tested in light of the hypothesis that BMDMCs
may exert distinctive effects on lung inflammation and
remodeling depending on the initial insult. To this end,
murine models of LPS and CLP-induced pulmonary in-
jury [8] were used, and lung mechanics, histology, and
humoral and cellular parameters of lung inflammation
and remodeling were analyzed at 1, 3 and 7 days after
induction of ARDS.
Methods
This study was approved by the Ethics Committee of the
Carlos Chagas Filho Institute of Biophysics, Health Sciences
Center, and Federal University of Brazil (CEUA-CCS,
IBCCF 019). All animals received humane care in compli-
ance with the Principles of Laboratory Animal Care formu-
lated by the National Society for Medical Research and the
Guide for the Care and Use of Laboratory Animals pre-
pared by the US National Academy of Sciences.
Cell isolation
BMDMCs were isolated from the femurs and tibiae of
8-week-old BALB/c mice as described previously [2].
Briefly, bone marrow cells from male BALB/c mice were
flushed from femurs and tibias with Dulbecco’s modi-
fied Eagle’s medium. After a homogeneous cell suspen-
sion was achieved, cells were centrifuged (400×g for 10
minutes), resuspended in Dulbecco’s modified Eagle’s
medium and added to Ficoll-Hypaque. The isolated cells
were counted in a Neubauer chamber with Trypan Blue
for evaluation of viability. Saline or BMDMCs were
injected into the jugular vein.Experimental protocol
BALB/c mice (age 8 to 10 weeks) were used: 98 females
and 10 male donors (weight 20 to 25 g). Numbers were
given to each cage and letters were given to each experi-
mental group for the randomization process, and after-
wards each number was linked to a letter. A member of
the laboratory that was blind to the experimental pro-
cedure performed the randomization process. Animals
in the control groups received saline intraperitoneally
(0.5 ml, group C) or were subjected to sham surgery
(sham group). Mice in the ARDS groups received E. coli
LPS intraperitoneally (5 mg/kg in 0.5 ml saline; LPS
group) or underwent CLP (Figure 1). In the CLP groups,
polymicrobial sepsis was induced as described previously
[8]. Briefly, animals were anesthetized with sevoflurane
and a midline laparotomy was performed. The cecum
was carefully isolated and a 3–0 cotton ligature was
placed below the ileocecal valve to prevent bowel ob-
struction. Finally, the cecum was punctured twice with
an 18-gauge needle [8]. In the sham group, an abdom-
inal incision was made with no cecal ligation and perfor-
ation. Both layers of the abdominal cavity were closed
with 3.0 silk sutures, followed by fluid resuscitation
with 0.5 ml/10 g body weight of prewarmed sterile sa-
line subcutaneously. Sham and CLP animals received
tramadol (0.05 mg/kg body weight subcutaneously) for
postoperative analgesia, repeated every 8 hours. After
this step, animals returned to their cages, where they
received water and food ad libitum. All manipulations
described were performed by the same investigator to
ensure consistency. Twenty-four hours after lung injury,
animals in group C and the ARDS group were further
randomized to receive saline (0.05 ml) or BMDMCs (2 ×
106 BMDMCs in 0.05 ml saline) intravenously. At day 1,
these models had similar degrees of lung mechanical com-
promise [8].
Lung mechanics
On days 1, 3 and 7 after induction of ARDS, mice were se-
dated (diazepam 1 mg intraperitoneally), anesthetized (thio-
pental sodium 20 mg/kg intraperitoneally), tracheotomized,
paralyzed (vecuronium bromide, 0.005 mg/kg intraven-
ously), and mechanically ventilated with the following
settings: respiratory frequency 100 breaths/minute, tidal
volume 0.2 ml, and fraction of inspired oxygen 0.21. The
anterior chest wall was surgically removed and a positive
end-expiratory pressure of 2 cmH2O was applied. After a
10-minute ventilation period, lung mechanics were
computed. At the end of the experiment (approxi-
mately 30 minutes), the lungs were prepared for hist-
ology and molecular biology. Airflow, volume and
tracheal pressure were measured [9]. In an open chest
preparation, tracheal pressure reflects transpulmonary
pressure. Static lung elastance (Est,L) was computed
Figure 1 Flowchart and timeline of study design. Control (group C) animals received saline intraperitoneally (ip). LPS group animals received
Escherichia coli lipopolysaccharide intraperitoneally. CLP group animals were subjected to cecal ligation and puncture. A sham-operated group
was used as control for animals undergoing CLP. At day 1, some animals were sacrificed, post acute respiratory distress syndrome (ARDS), to
evaluate lung function and histology, while other animals were further randomized into subgroups to receive saline (SAL) or bone marrow-
derived mononuclear cells (BMDMCs, 2 × 106 cells) intravenously (iv). Animals were euthanized at days 1, 3 and 7.
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InfoData, Inc., Montreal, Quebec, Canada).
Lung histology
Laparotomy was performed immediately after determin-
ation of lung mechanics. Heparin was injected intraven-
ously, the trachea was clamped at end expiration, and
the abdominal aorta and vena cava were sectioned. The
right lung was removed, fixed in 4% buffered formalde-
hyde, embedded in paraffin, and cut into slices 4 μm
thick, which were stained with hematoxylin and eosin
(Vetec Química Fina, Rio de Janeiro, Brazil).
The volume fraction of collapsed and normal pulmonary
areas and the number of macrophages and neutrophils in
pulmonary tissue were determined by the point-counting
technique at a magnification of ×200 across 10 random,
noncoincident microscopic fields [10]. Collagen fibers
(picrosirius polarization method) [11] were quantified inthe alveolar septa and expressed as the percentage of col-
lagen fibers per tissue area.
Inflammatory mediators and growth factor mRNA
expression
Quantitative real-time reverse transcription polymerase
chain reaction was performed to measure the relative levels
of mRNA expression of interleukin (IL)-1β, IL-6, IL-10,
keratinocyte-derived chemokine (KC), monocyte chemo-
tactic protein (MCP)-1, intercellular adhesion molecule
(ICAM)-1, vascular cell adhesion molecule (VCAM)-1,
and transforming growth factor beta (TGF-β). Slices were
obtained from the center of the left lung, collected in
cryotubes, quick-frozen by immersion in liquid nitrogen
and stored at −80°C. Total RNA was extracted from the
frozen tissues using the SV Total RNA Isolation System
(Promega, Rio de Janeiro, Brazil) according to the manu-
facturer’s instructions. RNA concentrations were measured


















Figure 2 Survival curves. Survival curves in animals after bone
marrow-derived mononuclear cells (BMDMC) or saline (SAL)
treatment after induction of sepsis by cecal ligation and puncture
(CLP) and in their respective control (sham) over 7 days. In the
CLP-BMDMC group, the survival rate was 70% on day 7.
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Technologies, Inc. 3411 Silverside Road. Bancroft Building.
Wilmington, DE 19810 USA). First-strand cDNA was syn-
thesized from total RNA using the GoTaq® 2-Step RT-
qPCR System (Promega), according to the manufacturer’s
recommendations. Relative mRNA levels were measured
with a SYBR green detection system using a Mastercycler
ep realplex2 S (Eppendorf, São Paulo, Brazil). All samples
were measured in triplicate. The relative amount of expres-
sion of each gene was calculated as the ratio of studied
gene to a control gene (acidic ribosomal phosphoprotein
P0 (36B4)) and expressed as the fold-change relative to
their respective control (group C or sham group).
The following polymerase chain reaction primers were
used: IL-1β, forward 5′-GTT GAC GGA CCC CAA
AAG-3′ and reverse 5′-GTG CTG CTG CGA GAT
TTG-3′, 93 base pairs (bp); IL-6, forward 5′-TCT CTG
GGA AAT CGT GGA A-3′ and reverse 5′-TCT GCA
AGT GCA TCA TCG T-3′, 81 bp; IL-10, forward 5′-
TCC CTG GGT GAG AAG CTG-3′ and reverse 5′-
GCT CCA CTG CCT TGC TCT-3′, 91 bp; KC, forward
5′-TGA AGC TCC CTT GGT TCA G-3′ and reverse
5′-GGT GCC ATC AGA GCA GTC T-3′, 91 bp; MCP-
1, forward 5′-CTT CTG GGC CTG CTG TTC A-3′
and reverse 5′-CCA GCC TAC TCA TTG GGA TCA-
3′, 127 bp; ICAM-1, forward 5′-CCG CAG GTC CAA
TTC ACA CT-3′ and reverse 5′-TCC AGC CGA GGA
CCA TAC AG-3′, 143 bp; VCAM-1, forward 5′-GTG
AAG ATG GTC GCC GTC TT-3′ and reverse 5′-GGC
CAT GGA GTC ACC GAT T-3′, 126 bp; TGF-β, for-
ward 5′-ATA CGC CTG agt GGC TGT C-3′ and re-
verse 5′-GCC CTG TAT TCC GTC TCC T-3′, 77 bp;
and 36B4 (Rplp0), forward 5′-CAA CCC AGC TCT
GGA GAA AC-3′ and reverse 5′-GTT CTG AGC
TGG CAC AGT GA-3′, 150 bp.
Inflammatory mediators and growth factor protein
expression
IL-1β, IL-6, IL-10, KC, MCP-1, and TGF-β protein expres-
sions were measured with ELISA kits accordingly to the
manufacturer's instructions (R&D Systems, Minneapolis,
MN, USA).
Bronchoalveolar lavage fluid
Bronchoalveolar lavage was carried out in the left lung via
a tracheal tube with phosphate-buffered saline solution
(0.5 ml) containing ethylenediamine tretraacetic acid
(10 mM). Total leukocyte numbers were measured in a
Neubauer chamber under light microscopy after diluting
the samples in Türk solution (2% acetic acid). Bronchoalve-
olar lavage fluid was centrifuged at 4°C for 10 minutes
at 400×g and the cell pellet resuspended in phosphate-
buffered saline for further leukocyte enumeration. The pro-
tein concentration was determined by the Bradford method.Differential cell counts were performed in cytospin smears
stained by the May–Grünwald–Giemsa method [2,3].
Statistical analysis
Comparison between control and sham groups was
performed at all endpoints (days 1, 3 and 7) using two-
way analysis of variance. Since lung function and histo-
logical data were not significantly different at these time
points, we decided to show only one control group.
Between-group differences were therefore assessed using
one-way analysis of variance followed by Bonferroni’s
post-hoc test. Survival curves were derived by the
Kaplan–Meier method and compared by log-rank test.
The significance level was set at 5%. All tests were
performed in GraphPad Prism 5.0 (GraphPad Software,
San Diego, CA, USA).
Results
Survival curve
At day 7, the survival rate of groups C, LPS-SAL and
LPS-BMDMC was 100%. Similarly, the sham mice sur-
vival rate was 100%. The CLP-SAL group had a survival
rate of 40%. BMDMC administration improved survival
in CLP animals (70% at day 7) (P <0.05) (Figure 2). Even
though the mortality rate in the LPS-treated and CLP-
treated animals was not comparable, the degrees of lung
mechanical compromise were similar.
BMDMC administration improved lung mechanics and
morphometry in both models of extrapulmonary ARDS
Est,L was higher in LPS animals than in controls on day 1.
Nevertheless, Est,L in LPS-SAL mice was not increased
compared with controls at days 3 and 7 (Figure 3). Est,L
was higher in CLP animals than in sham animals on day 1.
Est,L remained elevated in CLP-SAL mice at days 3 and 7.
BMDMC administration led to a significant reduction in












































Figure 3 Static lung elastance on days 1, 3 and 7. Mice received Escherichia coli lipopolysaccharide (LPS) intraperitoneally or were subjected
to cecal ligation and puncture (CLP). The control group for LPS received saline intraperitoneally, whereas a sham-operated group was used as
control for animals undergoing CLP. At day 1, some animals were sacrificed, post acute respiratory distress syndrome (ARDS), in order to evaluate
the static lung elastance (Est,L), while other animals were randomized and received saline (SAL) or bone marrow-derived mononuclear cells
(BMDMC, 2×106 cells) intravenously. Values expressed as mean ± standard deviation of six animals in each group. *Significantly different from the
corresponding control group (C or sham) (P <0.05). #ARDS-BMDMC vs. ARDS-SAL (P <0.05).
Maron-Gutierrez et al. Stem Cell Research & Therapy 2013, 4:123 Page 5 of 13
http://stemcellres.com/content/4/5/123At day 1, both LPS and CLP groups presented intersti-
tial edema, formation of hyaline membrane, neutrophil
infiltration and alveolar collapse (Figures 4 and 5). The
fraction area of alveolar collapse was higher both in LPS
(Figure 4A, Table 1) and in CLP (Figure 5A, Table 1) un-
treated mice at days 1, 3 and 7. BMDMC administration
led to a reduction in alveolar collapse at days 3 and 7,
regardless of the initial insult implicated in the patho-
genesis of ARDS (Figures 4A and 5A, Table 1).
Neutrophil counts in lung tissue were increased in
LPS mice compared with controls at all time points,
most prominently on day 1 (Figure 4B). BMDMC
administration reduced neutrophils at days 3 and 7
(Figure 4B). Macrophages and total cell counts in lung
tissue were increased in LPS mice compared with con-
trols at days 1, 3 and 7 (Figure 4B). Macrophages and
total cell counts were decreased in LPS-BMDMC ani-
mals at days 3 and 7 (Figure 4B). In untreated CLP mice,
the number of neutrophils in lung tissue was higher than
in sham mice at all time points, most prominently on
day 7 (Figure 5B). BMDMC administration reduced neu-
trophil counts at day 7 (Figure 5B). Macrophage and
total cell counts in lung tissue were higher in CLP mice
than in sham mice at days 1, 3 and 7 (Figure 5B).
BMDMC administration reduced macrophage and total
cell counts at days 3 and 7 (Figure 5B).
Effects of BMDMCs on inflammatory mediators in the
lung
The increase in inflammatory cell count in lung tissue
was accompanied by a significant increase in lung tissue
levels of inflammatory mediator mRNA expression in
the saline-treated groups. IL-1β and IL-10 wereincreased on day 1 in the LPS-SAL group. Nevertheless,
this increase was not sustained over time (Figure 4C). In
CLP-SAL, the increase in IL-1β mRNA expression was
observed at a later time point, at days 3 and 7 (Figure 5C).
No significant differences were observed in IL-10 mRNA
expression in the CLP-SAL group (Figure 5C) and in IL-6
mRNA expression in both CLP and LPS groups.
BMDMCs reduced IL-1β mRNA expression in the LPS
groups (Figure 4C) and CLP groups (Figure 5C). Levels of
MCP-1 and KC mRNA expression were high on day 1 in
the LPS-SAL group (Figure 4C), whereas in the CLP-SAL
group both KC and MCP-1 were increased on day 3
(Figure 5C). In LPS-BMDMC mice, cell therapy aug-
mented MCP-1 mRNA expression on day 3 and KC
mRNA expression on day 7 (Figure 4C).
We also analyzed protein expressions of IL-1β, IL-6,
IL-10, KC and MCP-1. At day 1 there was an increase in
IL-1β, KC and MCP-1 protein expression, while at day 7
there was a decrease in IL-6, IL-10, KC and MCP-1 pro-
tein expressions in the LPS-SAL group (Figure 4D).
Interestingly, at day 7 BMDMC therapy led to an in-
crease of these mediators’ levels compared with LPS-
SAL, returning to control values (Figure 4D). In the
CLP-SAL group, there was an increase in IL-1β and IL-
10 at days 3 and 7, and in MCP-1 at day 3 (Figure 5D).
In CLP-BMDMC mice, cell therapy increased IL-6 ex-
pression at day 7, and IL-10 and MCP-1 at days 3 and 7.Effects of BMDMCs on influx of inflammatory cells and
protein permeability in the alveolus
The increase in lung tissue levels of inflammatory media-




C ARDS-BMDMC Day 3 ARDS-BMDMC Day 7 
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D 
Figure 4 Lung injury and inflammation in lipopolysaccharide-induced acute respiratory distress syndrome. Representative
photomicrographs (×200 magnification) of lung tissue stained with hematoxylin and eosin (A), total and differential cell count in alveolar septa
(B), and levels of interleukin (IL)-1β, IL-6 and IL-10 and chemokines keratinocyte-derived chemokine (KC or CXCL1) and monocyte chemotactic
protein-1 (MCP-1 or CCL2) mRNA (C) and protein expressions (D) in lung tissue. Values expressed as mean ± standard deviation of six animals (B)
and of four to six animals (C, D) per group. *Significantly different from corresponding control group (C) (P <0.05). #ARDS-BMDMC vs. ARDS-SAL
(P <0.05). ARDS, acute respiratory distress syndrome; BMDMC, bone marrow-derived mononuclear cell; SAL, saline.
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(BALF) (Figure 6A,B) and an increase in lung protein per-
meability (Figure 6C). In LPS groups, the total number ofcells in BALF was increased at days 1 and 3 (Figure 6A).
BMDMC administration resulted in a decrease in total
cell infiltration in BALF. Mononuclear cells were
A 
B 
Sham ARDS-BMDMC Day 3 ARDS-BMDMC Day 7 
CLP Day 1 ARDS-SAL Day 3 ARDS-SAL Day 7 
C 
D 
Figure 5 Lung injury and inflammation in cecal ligation and puncture-induced acute respiratory distress syndrome. Representative
photomicrographs (×200 magnification) of lung tissue stained with hematoxylin and eosin (A), total and differential cell count in alveolar septa
(B), and levels of interleukin (IL)-1β, IL-6 and IL-10 and chemokines keratinocyte-derived chemokine (KC or CXCL1) and monocyte chemotactic
protein-1 (MCP-1 or CCL2) mRNA (C) and protein expressions (D) in lung tissue. Values expressed as mean ± standard deviation of six animals
(B) and four to six animals (C, D) per group. *Significantly different from corresponding control group (sham) (P <0.05). #ARDS-BMDMC vs. ARDS-
SAL (P <0.05). ARDS, acute respiratory distress syndrome; BMDMC, bone marrow-derived mononuclear cell; SAL, saline.
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Table 1 Morphometric parameters
Group Normal area (%) Alveolar collapse (%) Hyperinflation (%)
LPS CLP LPS CLP LPS CLP
C (LPS) or sham (CLP) 99.6 ± 0.7 99.0 ± 1.2 0.4 ± 0.7 1.0 ± 1.2 0.0 ± 0.0 0.0 ± 0.0
Day 1 ARDS 85.0 ± 7.0* 92.0 ± 3.3* 13.4 ± 6.0* 5.6 ± 4.0* 1.6 ± 3.0 0.0 ± 0.0
Day 3 ARDS-SAL 93.5 ± 2.4* 86.1 ± 4.2* 6.5 ± 2.4* 11.0 ± 1.7* 0.0 ± 0.0 2.9 ± 4.2*
ARDS-BMDMC 97.4 ± 1.5 94.6 ± 2.5# 2.6 ± 1.5 4.6 ± 2.4# 0.0 ± 0.0 0.0 ± 0.0
Day 7 ARDS-SAL 94.0 ± 1.0* 93.6 ± 2.9* 4.8 ± 2.0* 6.5 ± 2.8* 0.0 ± 0.0 0.3 ± 1.2
ARDS-BMDMC 98.8 ± 0.8 96.8 ± 2.2 1.2 ± 0.8 3.2 ± 2.2 0.0 ± 0.0 0.0 ± 0.0
Mice received Escherichia coli lipopolysaccharide (LPS) intraperitoneally or were subjected to cecal ligation and puncture (CLP) surgery. Control group animals received
saline intraperitoneally, whereas a sham-operated group was used as control for animals undergoing CLP. At day 1, some animals were sacrificed, post acute respiratory
distress syndrome (ARDS), to evaluate lung morphometry, while other animals were further randomized into subgroups to receive saline (SAL) or bone marrow-derived
mononuclear cells (BMDMC, 2×106 cells) intravenously. Values expressed as mean ± standard deviation of sic animals in each group. All values were computed in 10
random, noncoincident fields per animal. *Significantly different from corresponding control group (control or sham) (P <0.05). #ARDS-BMDMC vs. ARDS-SAL (P <0.05).
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ences in polymorphonuclear cell count (Figure 6A). In
CLP groups there was an increase in the cell influx at
day 3, both mononuclear cells and polymorphonuclear
cells (Figure 6B). BMDMC therapy reduced mono-
nuclear and polymorphonuclear cell influx at day 3
(Figure 6B).
Effects of BMDMCs on pulmonary adhesion molecule
mRNA expression are dependent on the initial insult
Levels of ICAM-1 and VCAM-1 mRNA expression were
high on day 1 in the LPS-SAL group (Figure 7), whereas
in the CLP-SAL group these adhesion molecules were
increased on day 3 (Figure 7). In LPS-BMDMC mice,
cell therapy increased ICAM-1 mRNA expression on
day 7 (Figure 7), with no significant differences in
VCAM-1 mRNA expression; however, in CLP-BMDMC
mice, VCAM-1 was increased on day 7 (Figure 8), with-
out any increase in ICAM-1 mRNA expression.
BMDMCs reduced collagen fiber content in the lung
parenchyma
Both LPS-SAL and CLP-SAL mice had increased colla-
gen fiber content at days 3 and 7 (Figure 8). BMDMC
administration led to a significant decrease in collagen
content; nevertheless, these changes in lung parenchyma
were not associated with TGF-β mRNA and protein ex-
pression in lung tissue (Figure 8).
Discussion
In the present study, in support of our initial hypothesis,
BMDMC administration had distinct effects on adhesion
molecule mRNA expression levels depending on the pri-
mary insult, resulting in an increase in ICAM-1 after LPS-
induced ARDS, while increasing VCAM-1 levels after
CLP-induced ARDS at day 7. This is the first study to
compare cell therapy effects in two different experimentalmodels of extrapulmonary ARDS (LPS and CLP). In previ-
ous studies from our group [2,3] we observed that cell
therapy had distinct effects on lung inflammation and re-
modeling depending on ARDS etiology (pulmonary vs.
extrapulmonary). In this context, we hypothesized that
even in the same etiology of ARDS, depending on the
primary insult (LPS and CLP), cell therapy could have
beneficial yet distinct effects. Demonstrating this hy-
pothesis, in the clinical scenario when patients are
treated according to ARDS etiology (pulmonary vs.
extrapulmonary), we should be aware of therapy effects,
since there may be different outcomes related to lung
inflammation and remodeling.
In previous studies with LPS-induced ARDS [2,7,12,13]
and CLP-induced ARDS [4-6], bone marrow cells were ad-
ministered only a few hours after injury. This administra-
tion limits the applicability of results to clinical practice,
because the time course for lung damage is not taken into
consideration. In order to produce a more clinically rele-
vant scenario, in the present study BMDMCs were
injected intravenously 1 day after the initial insult (LPS or
CLP), once the lung mechanical and morphologic changes
had already been established [6,8,14,15]. The effects of
BMDMC therapy were evaluated at days 3 and 7. We are
aware that most previous studies of ARDS have used
mesenchymal stromal cells; nevertheless, mesenchymal
stromal cells require culture conditions that are detri-
mental for cell transplantation and pose a risk of con-
tamination and immunological reactions. Bearing these
limitations in mind, and on the basis of some promis-
ing results from previous research conducted by our
group [2,6,12,16,17], we employed BMDMCs because
they can be easily and safely administered on the day of
harvest and are known to reduce lung inflammation
and fibrogenesis and thus restore lung function
[2,6,12,17,18]. Because it has already been demon-



























































































































































































Figure 6 Total and differential cell count and protein level in bronchoalveolar lavage fluid. Total white blood cell (WBC) and differential
cell count in bronchoalveolar lavage fluid (BALF) in the lipopolysaccharide (LPS) (A) and cecal ligation and puncture (CLP) (B) groups, as well as
BALF protein levels (C). Values expressed as mean ± standard deviation of four to six animals per group. *Significantly different from
corresponding control group (C or sham) (P <0.05). #ARDS-BMDMC vs. ARDS-SAL (P <0.05). ARDS, acute respiratory distress syndrome; BMDMC,
bone marrow-derived mononuclear cell; MN, mononuclear; PMN, polymorphonuclear; SAL, saline.
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we did not address this issue.
Several studies have suggested that the endothelium
plays an important role in the pathophysiology of sepsis
[19]. Our results suggest endothelial cell activation by
increased expression of cell adhesion molecules and in-
creased production of cytokines. Adhesion molecules
(ICAM-1 and VCAM-1) of endothelial cells interact
with integrins expressed on neutrophils that stabilize
cell–cell interactions, providing firm adherence and thus
facilitating cell transmigration [20]. ICAM-1 mRNA ex-
pression increased after intratracheal administration of
endotoxin or CLP-induced ARDS, in accordance with
previous studies [21-23]. Nevertheless, despite theincrease in mRNA expression of ICAM-1 and VCAM-1
as well as chemokines (MCP-1 and KC), BMDMC admin-
istration resulted in fewer mononuclear and polymorpho-
nuclear cells within the lung parenchyma. Nevertheless,
we observed an increase in BALF mononuclear cells in
both LPS-SAL and LPS-BMDMC groups at day 3. Add-
itionally, when KC protein expression was analyzed we did
not observe an increase after BMDMC therapy, in accord-
ance with our polymorphonuclear cell count findings.
BMDMC administration reined in the inflammatory
process, reducing inflammatory cell counts and modu-
lating the levels of inflammatory mediators (such as
IL-1β and IL-10) in lung tissue. IL-10 appears to play a























































































































Figure 7 Intracellular adhesion molecule-1 and vascular cell adhesion molecule-1. Intracellular adhesion molecule (ICAM)-1 and vascular
cell adhesion molecule (VCAM)-1 levels in lung tissue after lipopolysaccharide (LPS)-induced and cecal ligation and puncture (CLP)-induced acute
respiratory distress syndrome (ARDS). Values expressed as mean ± standard deviation of four animals per group. *Significantly different from
corresponding control group (C or sham) (P <0.05). BMDMC, bone marrow-derived mononuclear cell; SAL, saline.
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tion, and has been proposed as a key mediator of benefi-
cial effects in CLP-induced experimental sepsis [5].
Nevertheless, other studies investigating bone marrow
cell therapy, including those previously conducted by
our group, suggest that the beneficial effects of
BMDMC extend beyond an effect on a single mediator
[2,4,6]. IL-1β is mainly produced by activated macro-
phages as a pro-peptide and is cleaved by caspase-1
within the inflammasome into an active enzyme [24].
IL-1β can upregulate cell-surface expression of leukocyte
and vascular adhesion molecules and stimulate the pro-
duction of chemokines required for leukocyte recruitment
and activation [25]. Increased levels of IL-1β in ARDS
patients correlate with development of pulmonary fibrosis
[17,26]. In this context, we observed that BMDMC de-
creased lung collagen fiber content both in the LPS and
CLP groups. Nevertheless, this reduction was not associ-
ated with differences in TGF-β mRNA and proteinexpressions in lung tissue, suggesting another signaling
pathway (for example, collagenases) [3].
Studies using endotoxin models for the induction of
sepsis have provided a wealth of important knowledge.
Nevertheless, the clinical relevance of the LPS experimen-
tal model has been questioned, as administration of a
bolus of endotoxins does not reflect the complex patho-
physiology of sepsis [27]. Alternative experimental models
of sepsis have thus been proposed [28], such as CLP, a
model of polymicrobial sepsis [27,29,30]. Polymicrobial
sepsis and endotoxemia have been reported to have differ-
ing temporal cytokine responses, innate defense mecha-
nisms, and signaling molecules involved [31], which is
consistent with our findings. Additionally, as recently de-
fined by the American Thoracic Society [32], the diagnosis
of ARDS in animals should be based on at least three of
four main features of evidence: histology, inflammation,
physiological dysfunction, and permeability. Our experi-































































































































Figure 8 Collagen fiber and transforming growth factor beta. Collagen fiber content in alveolar septa and transforming growth factor beta
(TGF-β) mRNA and protein levels in lung tissue after lipopolysaccharide (LPS)-induced and cecal ligation and puncture (CLP)-induced acute
respiratory distress syndrome (ARDS). Values are mean ± standard deviation of four to six animals per group. *Significantly different from
corresponding control group (C or sham) (P <0.05). #ARDS-BMDMC vs. ARDS-SAL (P <0.05). BMDMC, bone marrow-derived mononuclear cell;
SAL, saline.
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physiological dysfunction, meeting the American Thoracic
Society criteria.
In this context, our study has some limitations. First,
mortality was higher in the ARDS-CLP group (60%)
than in the ARDS-LPS group (0%). Second, the CLP
model is one in which there is an ongoing septic insult,
with worsening injury over time. In contrast, the LPS
model is one of a single insult, making it difficult to
compare BMDMC effects across models. We plan future
studies to compare the BMDMC therapy in two bacterial
(septic) models. Third, inflammatory mediators were
measured in lung tissue. The balance between local
and systemic inflammation was therefore not evaluated.
Fourth, collagen fiber content was evaluated using a hist-
ology technique, but future studies should be performed
using either hydroxyproline or soluble collagen assay.
Fifth, the study endpoint was 7 days after LPS adminis-
tration or CLP for induction of ARDS. Nonetheless, to
better evaluate the effects of BMDMC therapy on lung
inflammation and remodeling, further studies of latertime points would be interesting. Sixth, previous studies
have used fibroblasts as control cells for cell therapy
studies [7,13,33]; however, some have demonstrated
that administration of fibroblasts, mesenchymal cells
without stem cell properties, may not only be ineffective
but may worsen injury [7,13,33,34]. Accordingly, saline
was chosen as the control. Finally, the effects of
BMDMCs on adhesion molecules might be of interest;
however, further research, such as the use of knockout
mice, is required to assess this issue.
Conclusions
Specific beneficial effects of BMDMC therapy were observed
for each type of initial insult triggering extrapulmonary
ARDS. BMDMC therapy at day 1, once lung mechan-
ical and histological changes had already been installed
in ARDS, successfully reduced inflammation and re-
modeling in both extrapulmonary ARDS models. These
data may be useful in the clinical setting, as they sug-
gest that the type of insult plays an essential role in the
outcome of ARDS treatment.
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